|
|
News Breaks | | | | February 5, 2013 | | 08:31 EDT |  | NKTR | Nektar announces initiation of Phase 2 study of etirinotecan pegol
Nektar announced the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The primary endpoint of the Phase 2 study is overall response rate. Secondary endpoints include progression free survival, overall survival, median duration of response and the safety profile of etirinotecan pegol in patients with NSCLC after failure of second-line therapy. The open label, single-arm trial is expected to enroll approximately 37 patients who will receive etirinotecan pegol once every three weeks as monotherapy. | |
|
News For NKTR From The Last 14 Days Check below for free stories on NKTR the last two weeks. |
|
|
| May 21, 2013 | | 09:29 EDT | | NKTR | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | May 17, 2013 | | 10:36 EDT |  | NKTR | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
 Subscribe for More Information | | | May 10, 2013 | | 10:37 EDT |  | NKTR | Nektar shares should be bought on weakness, says MKM Partners
Subscribe for More Information | | | May 9, 2013 | | 16:26 EDT |  | NKTR | Nektar reports Q1 EPS (48c), consensus (42c)
Subscribe for More Information | |
|
|
|
|
|
|
